Do You Need a DEA License in Every State You Prescribe?

If you prescribe controlled substances to patients in a given state, you generally need a DEA registration tied to a physical address in that state, separate from your medical license there and separate from any registration you already hold elsewhere. A DEA registration currently costs $888 for a three-year term, and roughly 20 to 25 states layer their own controlled-substance registration on top of it, often another $40 to a few hundred dollars a year. The decision that actually matters for a multi-state telepsychiatry practice is whether the math favors registering everywhere you have controlled-substance patients, or capping controlled prescribing to your home state and handling everyone else a different way.

This post covers the registration and pharmacy layer only. If you haven't already confirmed that telehealth-only controlled-substance prescribing is legal at all right now, read prescribing controlled substances by telehealth first; that page covers the Ryan Haight Act and the DEA's telemedicine flexibilities, which are a different question from the one below.

Do you need a DEA registration in every state you prescribe controlled substances?

Generally, yes, and the DEA says so directly: "a practitioner who maintains a professional practice location in multiple states" must obtain "a separate registration... for each principal place of business or professional practice," according to the DEA Diversion Control Division's own registration FAQ. A DEA registration is built on top of a state medical license, but it is not the same thing as one, and holding a license in a state does not by itself authorize you to prescribe controlled substances from there.

The telehealth wrinkle is where prescribers get tripped up. Your state medical license rule follows the patient: you need a license in whatever state your patient is physically sitting in during the visit, which is the question our IMLC and multi-state licensing guide answers. Your DEA registration rule follows you: the "principal place of business" is your own physical location while you write the prescription, not the patient's. A psychiatrist who lives and practices from one state, seeing patients located in ten others, generally needs only one DEA registration, because she has only one practice location. The moment she opens a second physical office, or physically relocates, in a state she also prescribes controlled substances from, she needs a second registration there too.

That distinction is genuinely confusing even to people whose job is answering it. In one case a practitioner relocating to a new state while continuing to see only her original state's patients called the DEA's national line for a straight answer and was told the line couldn't interpret pending rules and to call the regional office, which never called back. "Generally yes, tied to your physical location, confirm with your regional DEA office" is the honest answer here, ambiguity and all.

What does registering in a second state actually cost?

The DEA registration fee itself is a hard number: $888 for a three-year term, set in a 2020 final rule and unchanged since, per the Federal Register. The fee is nonrefundable even if the application is denied. On top of that hard number sit two variable costs: an optional state controlled-substance registration (below) and a physical address in the new state, since the DEA does not accept a bare PO box and enforces the "real office" requirement inconsistently. A registered-agent address running about $175 a year has satisfied the DEA for some prescribers; a staffed virtual office with mail forwarding runs closer to $700 a year; and at least one prescriber describes a registered-agent address working fine until a DEA agent called to ask her to describe her actual office before anything else would move forward.

Putting the three line items together into a build-your-own estimate, not an official fee schedule, the carrying cost scales roughly like this:

The ranges widen because the state CDS registration and the address overhead vary so much by state. This table prices the DEA and controlled-substance layer only; the separate cost of the state medical licenses themselves, which our multi-state licensing guide estimates at roughly $1,500 per state per renewal cycle, stacks on top of it. Picking the actual address to put on each registration is its own decision with its own failure modes, covered in choosing a practice address for telehealth.

Do you also need a state controlled-substance registration?

In a meaningful share of states, yes, on top of the DEA registration, not instead of it. Compliance trackers put the count at roughly 20 to 25 states that layer their own controlled-substance registration or license requirement, states like New Jersey, Connecticut, and Illinois among them, typically in the tens of dollars a year rather than hundreds, though fees and requirements change and vary enough by state that you should check your target state's board of pharmacy or medical board directly rather than trust any list, including this one, as current. A handful of large states, Texas and California among them, historically have not required a separate state CDS registration on top of the DEA. The pattern to remember: a DEA registration alone is not automatically the whole story in every state, so confirm the state layer every time you add one.

The decision: register everywhere, or cap controlled prescribing to your home state?

"Register where your controlled-substance patients actually are, and be honest about which states those are," says Juan Rodriguez, MD, who reviewed this guide. "The expensive mistake is treating a one-patient state like a market you have to keep."

Once you can see the real numbers, the decision usually comes down to how concentrated your controlled-substance patients are. Register in a state when you can already name a specific, ongoing reason: an established handful of patients there, a referral source that reliably sends more, or a market where you're actively building a presence. At that point, $770 to $1,450 a year is a rounding error against what those patients pay you.

Cap your controlled prescribing to your home state instead when your out-of-state patients are thin and scattered, one or two people in each of several states, with no concentration anywhere. In that case, two structures let you keep the patient relationship without the registration: see the patient for everything except the controlled medication and coordinate with a local prescriber who writes that one script, or take the relationship on a genuine consulting basis, where a psychiatrist licensed in the patient's own state remains the prescriber of record and you advise. Either one works only if you line up the real, named local colleague before you need them, while there's no urgency and you can pick well.

Why a valid out-of-state prescription still gets refused at the pharmacy

Federal law is more permissive here than most prescribers assume. The DEA's own guidance states it plainly: "Neither the Controlled Substances Act nor DEA regulations prohibit a pharmacist from filling a controlled substance prescription issued by a practitioner who is registered with DEA in a state other than the state in which the pharmacy is located," per the DEA's prescriptions FAQ. One prescriber holding only a home-state DEA registration has sent stimulant prescriptions into a dozen other states for years without a single refusal.

But pharmacists carry their own independent legal exposure, called corresponding responsibility: a pharmacist who fills a prescription lacking a legitimate medical purpose is liable alongside the prescriber, and "out-of-area doctor" is a documented red flag pharmacists are trained to weigh, according to pharmacy-law guidance on resolving prescription red flags. That is a real, separate reason for refusal that has nothing to do with whether your registration is valid. Large chains, Walgreens named most often in prescriber accounts, have turned away scripts over an out-of-area address even when nothing in federal law or the patient's state required it. In one documented case, a patient could not fill a benzodiazepine prescription at several pharmacies in his own state despite his prescriber holding a fully valid license and DEA registration there.

Two things help. Call the specific pharmacy location before the first fill and ask directly whether they will accept a controlled prescription from your registration; the answer tells you more in two minutes than any amount of researching the rule. And once you know which pharmacies in a patient's area reliably fill for you, route new patients there instead of discovering the refusal live.

The relocation trap: what happens to your registration when you move

Because a DEA registration follows your physical location, a personal move can force the entire decision above, whether or not you planned for it. A prescriber who relocates while continuing to see only her original state's patients by telehealth is, per the majority reading among prescribers who have asked, still required to register in the new state she is physically located in, even though she prescribes to nobody there. The registration tracks the prescriber's own location at the time of the visit, a fact that surprises people who assume it tracks the patient the way a medical license does.

Malpractice carriers add a layer some prescribers only discover after the fact. At least one carrier requires controlled-substance telehealth visits to be conducted from an office in the licensed state rather than a home office one state line away, a condition the carrier sets to price its own risk, independent of anything the DEA requires. If a move is on the horizon, price your registration and carrier requirements for the destination state before the move date, so the first bounced prescription isn't how you find out.

FAQ

Related guides: what you need to start a private practice sequences this alongside every other launch task, and the IMLC and multi-state licensing guide covers the state-license half of the multi-state decision.

This is general information for practice planning, not legal advice. DEA and state controlled-substance rules change and are interpreted inconsistently even by regulators; confirm anything load-bearing with your regional DEA office, your state board, and your malpractice carrier before you rely on it. This post cites the DEA's telemedicine flexibilities, currently extended through December 31, 2026; if that deadline moves, the linked telehealth guide is the one we update first.